HC Wainwright Predicts Prothena’s Q2 Earnings (NASDAQ:PRTA)

Prothena Corporation plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for Prothena in a note issued to investors on Friday, May 8th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of ($0.38) for the quarter, down from their previous forecast of $1.14. The consensus estimate for Prothena’s current full-year earnings is $0.99 per share. HC Wainwright also issued estimates for Prothena’s Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at $1.09 EPS and FY2029 earnings at ($1.24) EPS.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.91. The firm had revenue of $51.08 million for the quarter, compared to analysts’ expectations of $0.81 million. Prothena had a negative return on equity of 43.44% and a negative net margin of 260.92%.

PRTA has been the topic of several other research reports. Stifel Nicolaus set a $19.00 price objective on shares of Prothena in a report on Friday, March 13th. Citizens Jmp raised their target price on Prothena from $19.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Weiss Ratings lowered Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. Royal Bank Of Canada upped their price target on Prothena from $11.00 to $12.00 and gave the stock a “sector perform” rating in a research note on Friday, February 20th. Finally, Citigroup reiterated an “outperform” rating on shares of Prothena in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $21.78.

Prothena Stock Down 2.5%

Shares of NASDAQ PRTA opened at $9.43 on Wednesday. The firm has a market cap of $493.69 million, a PE ratio of -3.34, a P/E/G ratio of 0.28 and a beta of -0.23. The company’s fifty day simple moving average is $10.00 and its 200 day simple moving average is $9.80. Prothena has a 12-month low of $4.32 and a 12-month high of $11.80.

Institutional Investors Weigh In On Prothena

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its stake in Prothena by 650.1% during the 3rd quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 8,880 shares in the last quarter. ProShare Advisors LLC purchased a new position in Prothena during the fourth quarter worth about $100,000. Inscription Capital LLC bought a new stake in Prothena in the 3rd quarter worth about $102,000. PDT Partners LLC purchased a new stake in Prothena in the 4th quarter valued at about $108,000. Finally, DRW Securities LLC purchased a new stake in Prothena in the 4th quarter valued at about $114,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.